Skip Navigation

Cardiovascular Research 2002 56(1):104-117; doi:10.1016/S0008-6363(02)00509-6
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Caballero, R.
Right arrow Articles by Delpón, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, R.
Right arrow Articles by Delpón, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)

Ricardo Caballero*, Ignacio Moreno, Teresa González, Carmen Valenzuela, Juan Tamargo and Eva Delpón

Department of Pharmacology, School of Medicine, Universidad Complutense, 28040—Madrid, Spain

* Corresponding author. Tel.: +34-91-394-1474; fax: +34-91-394-1470 rcaballero{at}ift.csic.es

Objectives: It has been demonstrated that at nanomolar concentrations benzocaine increased, whereas at micromolar concentrations, it blocked hKv1.5 channels in a voltage-dependent manner and modified the voltage-dependence of channel activation. The present study was undertaken to localize the putative binding sites involved in the ‘agonists’ and blocking effects of benzocaine. Methods: Experiments were carried out on wild-type and site directed mutated hKv1.5 channels stably expressed on Ltk– cells using the whole-cell patch-clamp. Results: At 35 mM [K+]i the voltage-dependent unblock produced by 500 µM benzocaine was preserved at both 4 and 140 mM [K+]o. Mutations located in the inner mouth of the pore (T477S, T505A, L508M and V512M) abolished the agonist but increased the blocking effects of benzocaine. Intracellular application of tetraethylammonium (3 mM) abolished the ‘agonist’ effects whereas the blocking effects of benzocaine remained unaltered. Block induced by benzocaine and intracellular tetraethylammonium was additive. In contrast, the combination of benzocaine and bupivacaine (>25 µM) produced less blockade than bupivacaine alone. However, mutation of the extracellular residue R485Y did not modify the effects of benzocaine. Extracellular application of tetraethylammonium (100 mM) did not modify the agonist effects of benzocaine, but abolished the voltage- and time-dependence of benzocaine-induced block. Conclusions: The results suggested that benzocaine binds with high affinity to an intracellular binding site to produce ‘agonist’ effects and to a low affinity subsite, which is also located in the inner mouth, to produce the blocking effects. Furthermore, benzocaine and extracellular K+ interact to modify the voltage-dependence of channel opening.

KEYWORDS K-channel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.